Associate Professor Nick Lintzeris

BMedSci, MBBS, PhD
Clinical Associate Professor, Central Clinical School
Director and Senior Staff Specialist, Drug and Alcohol Services, South East Sydney Local Health District (SESLHD), NSW Health

Telephone +61 419261675

Map

Biographical details

Associate Professor Nicholas (Nick) Lintzeris is an Addiction Medicine specialist who has been involved for over two decades in clinical service delivery, research, professional education and policy activities in the field. He is internationally recognised as an expert in the treatment of opioid dependence, and has clinical and research interests in benzodiazepine, cannabis and psychostimulant use.

As Director of Drug and Alcohol (D&A) Services in South East Sydney Local Health District, he oversees the provision of varied clinical services via specialist community- and hospital-based settings, for individuals with substance use problems residing within a catchment area of approximately 850,000 people. Additionally, he is a practicing clinician. Between 2011-2013, Professor Lintzeris also served as Chief Addiction Medicine Specialist (part-time) for NSW Health, providing statewide leadership on policy for the D&A sector.

Previously Professor Lintzeris was a recipient of a NHMRC Clinical Research Postdoctoral Fellowship based at the National Addiction Centre in London, UK, where he held clinical and research appointments. He has been active in policy development, having served on national and statewide policy groups and consulted to the WHO Mental Health Division. Currently he is a member of the Drug and Alcohol Program Council in Australia. Professor Lintzeris has been involved in a range of clinical translational activities, including the development of clinical guidelines, e.g. the Australian Guidelines for Medication-Assisted Treatment of Opioid Dependence (including buprenorphine, methadone and naltrexone) and the Australian Guidelines for the Treatment of Alcohol Use Disorders. He is Foundation Fellow of the Addiction Medicine Chapter of the Royal Australasian College of Physicians.

Research interests

Professor Lintzeris works with several research teams in Australia and the UK, successfully bridging clinical and research communities. His primary research interest is the development and evaluation of treatment interventions and services for individuals with substance use disorders, with particular expertise in the evaluation of pharmacotherapies in treatment populations. He conducts treatment intervention studies, systematic reviews, service evaluation, health systems research, psychopharmacology, epidemiology and qualitative studies. He has a particular interest in the translation of research evidence into clinical practice.

Selected grants

2015

  • From ‘BIG DATA’ to evidence: Post-market surveillance of psychotropic medicines in Australia; Schneider C, Pearson S, Karanges E, McGregor I, Buckley N, McLachlan A, Wilson F, Marshall N, Hunt G, Allsop D, Bowen M, Hunt C, Russell J, Abbott M, Lintzeris N; DVC Research/HMR+ Implementation Fund - University.
  • An RCT of cannabinoid replacement therapy (Sativex®) for preventing relapse in treatment-resistant cannabis dependent patients; Lintzeris N, Allsop D, Copeland J, McGregor I, Dunlop A, Shanahan M, Bruno R; National Health and Medical Research Council (NHMRC)/Project Grants.

2014

  • Randomised control trial of exercise for the management of cannabis withdrawal in adult humans; Lintzeris N, McGregor I, Rooney K, Allsop D, Arnold J; National Health and Medical Research Council (NHMRC)/Project Grants.

2013

  • Randomised control trial of exercise for the management of cannabis withdrawal in adult humans; Lintzeris N; DVC Research/Bridging Support Grant.

2012

  • Health outcomes associated with long-term cannabis use; Johnston J, Lintzeris N, McGregor I; Health Administration Corporation/Drug and Alcohol Research Grant.

2009

  • Randomised, double-blind, placebo controlled trial of lithium carbonate for the management of human cannabis withdrawal; Lintzeris N, McGregor I, Winstock A, Guastella A; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The effects of mixing alcohol with presciption drugs upon driving performance: a randomised simulator study; Lintzeris N, Leung S, Lenne M, Haber P, Bruno R; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications & creative works

Download citations: PDF RTF Endnote

Book Chapters

  • Haber, P., Lintzeris, N., Morley, K. (2009). Pharmacotherapies for alcohol dependence. In Paul Haber, Elizabeth Proude, Nick Lintzeris & Olga Lopatko (Eds.), Guidelines for the Treatment of Alcohol Problems, (pp. 93-106). Australia: Commonwealth of Australia.

Journals

  • Degenhardt, L., Bruno, R., Lintzeris, N., Hall, W., Nielsen, S., Larance, B., Cohen, M., Campbell, G. (2015). Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): A cohort study. The Lancet Psychiatry, 2(4), 314-322. [More Information]
  • Nielsen, S., Lintzeris, N., Bruno, R., Campbell, G., Larance, B., Hall, W., Hoban, B., Cohen, M., Degenhardt, L. (2015). Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. Pain Medicine, 16(2), 356-366. [More Information]
  • Allsop, D., Lintzeris, N., Copeland, J., Dunlop, A., McGregor, I. (2015). Cannabinoid Replacement Therapy (CRT): Nabiximols (Sativex) as a Novel Treatment for Cannabis Withdrawal. Clinical Pharmacology & Therapeutics, 97(6), 571-574. [More Information]
  • Murnion, B., Lintzeris, N., Nielsen, S. (2015). Comparing treatment-seeking codeine users and strong opioid users: Findings from a novel case series. Knowledge Management Research, 34(3), 304-311. [More Information]
  • Degenhardt, L., Lintzeris, N., Campbell, G., Bruno, R., Cohen, M., Farrell, M., Hall, W. (2015). Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence, 147, 144-150. [More Information]
  • Larance, B., Carragher, N., Mattick, R., Lintzeris, N., Ali, R., Degenhardt, L. (2014). A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses? Drug and Alcohol Dependence, 142, 46-55. [More Information]
  • Lofwall, M., Martin, J., Tierney, M., Fatseas, M., Auriacombe, M., Lintzeris, N. (2014). Buprenorphine diversion and misuse in outpatient practice. Journal of Addiction Medicine, 8(5), 327-332. [More Information]
  • Campbell, G., Mattick, R., Bruno, R., Larance, B., Nielsen, S., Cohen, M., Lintzeris, N., Shand, F., Hall, W., Hoban, B., et al (2014). Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study. BMC Pharmacology & Toxicology, 15(1), 1-9. [More Information]
  • Belcher, J., Nielsen, S., Campbell, G., Bruno, R., Hoban, B., Larance, B., Lintzeris, N., Degenhardt, L. (2014). Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. Drug and Alcohol Review, 33(1), 27-32. [More Information]
  • Johnston, J., Lintzeris, N., Allsop, D., Suraev, A., Booth, J., Carson, D., Helliwell, D., Winstock, A., McGregor, I. (2014). Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. Psychopharmacology, 231(24), 4623-4636. [More Information]
  • Allsop, D., Copeland, J., Lintzeris, N., Dunlop, A., Montebello, M., Sadler, C., Rivas, G., Holland, R., Muhleisen, P., Norberg, M., Booth, J., McGregor, I. (2014). Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry, 71(3), 281-291. [More Information]
  • Larance, B., Lintzeris, N., Ali, R., Dietze, P., Mattick, R., Jenkinson, R., White, N., Degenhardt, L. (2014). The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug and Alcohol Dependence, 136(1), 21-27. [More Information]
  • Lintzeris, N., Leung, S., Dunlop, A., Larance, B., White, N., Rivas, G., Holland, R., Degenhardt, L., Muhleisen, P., Hurley, M., et al (2013). A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug and Alcohol Dependence, 131(1-2), 119-126. [More Information]
  • Holliday, S., Magin, P., Dunbabin, J., Oldmeadow, C., Henry, J., Lintzeris, N., Attia, J., Goode, S., Dunlop, A. (2013). An Evaluation of the Prescription of Opioids for Chronic Nonmalignant Pain by Australian General Practitioners. Pain Medicine, 14(1), 62-74. [More Information]
  • Holliday, S., Magin, P., Oldmeadow, C., Attia, J., Dunbabin, J., Henry, J., Lintzeris, N., Goode, S., Dunlop, A. (2013). An examination of the influences on New South Wales general practitioners regarding the provision of opioid substitution therapy. Drug and Alcohol Review, 32(5), 495-503. [More Information]
  • Nielsen, S., Larance, B., Lintzeris, N., Black, E., Bruno, R., Murnion, B., Dunlop, A., Degenhardt, L. (2013). Correlates of pain in an in-treatment sample of opioid-dependent people. Drug and Alcohol Review, 32(5), 489-494. [More Information]
  • Wong, A., Montebello, M., Norberg, M., Rooney, K., Lintzeris, N., Bruno, R., Booth, J., Arnold, J., McGregor, I. (2013). Exercise increases plasma THC concentrations in regular cannabis users. Drug and Alcohol Dependence, 133(2), 763-767. [More Information]
  • Nielsen, S., Bruno, R., Degenhardt, L., Stoove, M., Fischer, J., Carruthers, S., Lintzeris, N. (2013). The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. Medical Journal of Australia, 199(10), 696-699. [More Information]
  • Groshkova, T., Metrebian, N., Hallam, C., Charles, V., Martin, A., Forzisi, L., Lintzeris, N., Strang, J. (2013). Treatment expectations and satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the Randomised Injectable Opiate Treatment Trial, the UK's first supervised injectable maintenance clinics. Drug and Alcohol Review, 32(6), 566-573. [More Information]
  • Day, C., Demirkol, A., Tynan, M., Curry, K., Hines, S., Lintzeris, N., Haber, P. (2012). Individual versus team-based case-management for clients of opioid treatment services: An initial evaluation of what clients prefer. Drug and Alcohol Review, 31(4), 499-506. [More Information]
  • Black, K., Haber, P., Lintzeris, N. (2012). Offering incentives to drug-using women to take up contraception: The ethical and clinical issues. Addiction, 107(7), 1361-1362. [More Information]
  • Black, K., Stephens, C., Haber, P., Lintzeris, N. (2012). Unplanned pregnancy and contraceptive use in women attending drug treatment services. Australian and New Zealand Journal of Obstetrics and Gynaecology, 52(2), 146-150. [More Information]
  • Winstock, A., Lintzeris, N., Lea, T. (2011). 'Should I stay or should I go?' Coming off methadone and buprenorphine treatment. International Journal of Drug Policy, 22(1), 77-81. [More Information]
  • Larance, B., Degenhardt, L., Lintzeris, N., Winstock, A., Mattick, R. (2011). Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug and Alcohol Review, 30(3), 236-245. [More Information]
  • Longman, C., Lintzeris, N., Temple-Smith, M., Gilchrist, G. (2011). Methadone and buprenorphine prescribing patterns of Victorian general practitioners: Their first 5 years after authorisation. Drug and Alcohol Review, 30(4), 355-359. [More Information]
  • Mayet, S., Gossop, M., Lintzeris, N., Markides, V., Strang, J. (2011). Methadone maintenance, QTc and torsade de pointes: Who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug and Alcohol Review, 30(4), 388-396. [More Information]
  • Nielsen, S., Bruno, R., Lintzeris, N., Fischer, J., Carruthers, S., Stoové, M. (2011). Pharmaceutical opioid analgesic and heroin dependence: How do treatment-seeking clients differ in Australia? Drug and Alcohol Review, 30(3), 291-299. [More Information]
  • Larance, B., Degenhardt, L., Lintzeris, N., Bell, J., Winstock, A., Dietze, P., Mattick, R., Ali, R., Horyniak, D. (2011). Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence, 118(2011), 265-273. [More Information]
  • Douglas, H., Boyle, M., Lintzeris, N. (2011). The health impacts of khat: a qualitative study among Somali-Australians. Medical Journal of Australia, 195(11), 666-669. [More Information]
  • Lintzeris, N., Nielsen, S. (2010). Benzodiazepines, methadone and buprenorphine: interactions and clinical management. American Journal on Addictions, 19(1), 59-72. [More Information]
  • Lintzeris, N. (2010). Commentary on Blanken et al. (2010): long-term heroin-assisted treatment-some more questions and answers. Addiction, 105(2), 309-310. [More Information]
  • Sanson-Fisher, R., Brand, M., Shakeshaft, A., Haber, P., Day, C., Conigrave, K., Mattick, R., Lintzeris, N., Teesson, M. (2010). Forming a national multicentre collaboration to conduct clinical trials: increasing high-quality research in the drug and alcohol field. Drug and Alcohol Review, 29(5), 469-474. [More Information]
  • Forzisi, L., Mitchell, T., Bond, A., Lintzeris, N., Spofforth, N., Strang, J. (2010). Psychological Performance and Sedation Following Injectable Opioid Administration. Heroin Addiction and Related Clinical Problems, 12(3), 5-8.
  • Miller, P., McKenzie, S., Lintzeris, N., Martin, A., Strang, J. (2010). The Community Impact of RIOTT, a Medically Supervised Injectable Maintenance Clinic in South London. Mental Health and Substance Use, 3(3), 248-259. [More Information]
  • Ramasamy, P., Lintzeris, N., Sutton, Y., Taylor, H., Day, C., Haber, P. (2010). The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction, 105(2), 329-334. [More Information]
  • Ridge, G., Gossop, M., Lintzeris, N., Witton, J., Strang, J. (2009). Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Journal of Substance Abuse Treatment, 37(1), 95-100. [More Information]
  • Bammer,, G., Ritter, A., Kutin, J., Lintzeris, N. (2009). Fast-tracking implementation through trial design: the case of buprenorphine treatment in Victoria. Australian and New Zealand Journal of Public Health, 33(1), 34-39. [More Information]
  • Miller, P., Forzisi, L., Zador, D., Lintzeris, N., Metrebian, N., Waal, R., Mayet, S., Strang, J. (2009). Groin injecting in injectable opioid treatment service users in South London. Addiction Research and Theory, 17(4), 381-389. [More Information]
  • Degenhardt, L., Larance, B., Bell, J., Winstock, A., Lintzeris, N., Ali, R., Scheuer, N. (2009). Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Medical Journal of Australia, 191(3), 161-165. [More Information]
  • Lintzeris, N. (2009). Prescription of heroin for the management of heroin dependence: Current status. CNS Drugs, 23(6), 463-476. [More Information]
  • Winstock, A., Lintzeris, N., Lea, T. (2009). Why do patients report transferring between methadone and buprenorphine? Drug and Alcohol Review, 28(6), 686-687. [More Information]
  • Lintzeris, N., Lee, S., Scopelliti, L., Mabbutt, J., Haber, P. (2008). Unplanned admissions to two Sydney public hospitals after naltrexone implants. Medical Journal of Australia, 188(8), 441-444. [More Information]
  • Digiusto, E., Lintzeris, N., Breen, C., Kimber, J., Mattick, R., Bell, J., Ali, R., Saunders, J. (2005). Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addictive Behaviors, 30(3), 443-56. [More Information]

Research Reports

  • Haber, P., Lintzeris, N., Proude, E., Lopatko,, O. (2009). Guidelines for the Treatment of Alcohol Problems, Publications Number: P3 -5625, (pp. vii - 232). Canberra, Australia: Commonwealth Department of Health and Ageing.

2015

  • Degenhardt, L., Bruno, R., Lintzeris, N., Hall, W., Nielsen, S., Larance, B., Cohen, M., Campbell, G. (2015). Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): A cohort study. The Lancet Psychiatry, 2(4), 314-322. [More Information]
  • Nielsen, S., Lintzeris, N., Bruno, R., Campbell, G., Larance, B., Hall, W., Hoban, B., Cohen, M., Degenhardt, L. (2015). Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. Pain Medicine, 16(2), 356-366. [More Information]
  • Allsop, D., Lintzeris, N., Copeland, J., Dunlop, A., McGregor, I. (2015). Cannabinoid Replacement Therapy (CRT): Nabiximols (Sativex) as a Novel Treatment for Cannabis Withdrawal. Clinical Pharmacology & Therapeutics, 97(6), 571-574. [More Information]
  • Murnion, B., Lintzeris, N., Nielsen, S. (2015). Comparing treatment-seeking codeine users and strong opioid users: Findings from a novel case series. Knowledge Management Research, 34(3), 304-311. [More Information]
  • Degenhardt, L., Lintzeris, N., Campbell, G., Bruno, R., Cohen, M., Farrell, M., Hall, W. (2015). Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence, 147, 144-150. [More Information]

2014

  • Larance, B., Carragher, N., Mattick, R., Lintzeris, N., Ali, R., Degenhardt, L. (2014). A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses? Drug and Alcohol Dependence, 142, 46-55. [More Information]
  • Lofwall, M., Martin, J., Tierney, M., Fatseas, M., Auriacombe, M., Lintzeris, N. (2014). Buprenorphine diversion and misuse in outpatient practice. Journal of Addiction Medicine, 8(5), 327-332. [More Information]
  • Campbell, G., Mattick, R., Bruno, R., Larance, B., Nielsen, S., Cohen, M., Lintzeris, N., Shand, F., Hall, W., Hoban, B., et al (2014). Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study. BMC Pharmacology & Toxicology, 15(1), 1-9. [More Information]
  • Belcher, J., Nielsen, S., Campbell, G., Bruno, R., Hoban, B., Larance, B., Lintzeris, N., Degenhardt, L. (2014). Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. Drug and Alcohol Review, 33(1), 27-32. [More Information]
  • Johnston, J., Lintzeris, N., Allsop, D., Suraev, A., Booth, J., Carson, D., Helliwell, D., Winstock, A., McGregor, I. (2014). Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. Psychopharmacology, 231(24), 4623-4636. [More Information]
  • Allsop, D., Copeland, J., Lintzeris, N., Dunlop, A., Montebello, M., Sadler, C., Rivas, G., Holland, R., Muhleisen, P., Norberg, M., Booth, J., McGregor, I. (2014). Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry, 71(3), 281-291. [More Information]
  • Larance, B., Lintzeris, N., Ali, R., Dietze, P., Mattick, R., Jenkinson, R., White, N., Degenhardt, L. (2014). The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug and Alcohol Dependence, 136(1), 21-27. [More Information]

2013

  • Lintzeris, N., Leung, S., Dunlop, A., Larance, B., White, N., Rivas, G., Holland, R., Degenhardt, L., Muhleisen, P., Hurley, M., et al (2013). A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug and Alcohol Dependence, 131(1-2), 119-126. [More Information]
  • Holliday, S., Magin, P., Dunbabin, J., Oldmeadow, C., Henry, J., Lintzeris, N., Attia, J., Goode, S., Dunlop, A. (2013). An Evaluation of the Prescription of Opioids for Chronic Nonmalignant Pain by Australian General Practitioners. Pain Medicine, 14(1), 62-74. [More Information]
  • Holliday, S., Magin, P., Oldmeadow, C., Attia, J., Dunbabin, J., Henry, J., Lintzeris, N., Goode, S., Dunlop, A. (2013). An examination of the influences on New South Wales general practitioners regarding the provision of opioid substitution therapy. Drug and Alcohol Review, 32(5), 495-503. [More Information]
  • Nielsen, S., Larance, B., Lintzeris, N., Black, E., Bruno, R., Murnion, B., Dunlop, A., Degenhardt, L. (2013). Correlates of pain in an in-treatment sample of opioid-dependent people. Drug and Alcohol Review, 32(5), 489-494. [More Information]
  • Wong, A., Montebello, M., Norberg, M., Rooney, K., Lintzeris, N., Bruno, R., Booth, J., Arnold, J., McGregor, I. (2013). Exercise increases plasma THC concentrations in regular cannabis users. Drug and Alcohol Dependence, 133(2), 763-767. [More Information]
  • Nielsen, S., Bruno, R., Degenhardt, L., Stoove, M., Fischer, J., Carruthers, S., Lintzeris, N. (2013). The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. Medical Journal of Australia, 199(10), 696-699. [More Information]
  • Groshkova, T., Metrebian, N., Hallam, C., Charles, V., Martin, A., Forzisi, L., Lintzeris, N., Strang, J. (2013). Treatment expectations and satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the Randomised Injectable Opiate Treatment Trial, the UK's first supervised injectable maintenance clinics. Drug and Alcohol Review, 32(6), 566-573. [More Information]

2012

  • Day, C., Demirkol, A., Tynan, M., Curry, K., Hines, S., Lintzeris, N., Haber, P. (2012). Individual versus team-based case-management for clients of opioid treatment services: An initial evaluation of what clients prefer. Drug and Alcohol Review, 31(4), 499-506. [More Information]
  • Black, K., Haber, P., Lintzeris, N. (2012). Offering incentives to drug-using women to take up contraception: The ethical and clinical issues. Addiction, 107(7), 1361-1362. [More Information]
  • Black, K., Stephens, C., Haber, P., Lintzeris, N. (2012). Unplanned pregnancy and contraceptive use in women attending drug treatment services. Australian and New Zealand Journal of Obstetrics and Gynaecology, 52(2), 146-150. [More Information]

2011

  • Winstock, A., Lintzeris, N., Lea, T. (2011). 'Should I stay or should I go?' Coming off methadone and buprenorphine treatment. International Journal of Drug Policy, 22(1), 77-81. [More Information]
  • Larance, B., Degenhardt, L., Lintzeris, N., Winstock, A., Mattick, R. (2011). Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug and Alcohol Review, 30(3), 236-245. [More Information]
  • Longman, C., Lintzeris, N., Temple-Smith, M., Gilchrist, G. (2011). Methadone and buprenorphine prescribing patterns of Victorian general practitioners: Their first 5 years after authorisation. Drug and Alcohol Review, 30(4), 355-359. [More Information]
  • Mayet, S., Gossop, M., Lintzeris, N., Markides, V., Strang, J. (2011). Methadone maintenance, QTc and torsade de pointes: Who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug and Alcohol Review, 30(4), 388-396. [More Information]
  • Nielsen, S., Bruno, R., Lintzeris, N., Fischer, J., Carruthers, S., Stoové, M. (2011). Pharmaceutical opioid analgesic and heroin dependence: How do treatment-seeking clients differ in Australia? Drug and Alcohol Review, 30(3), 291-299. [More Information]
  • Larance, B., Degenhardt, L., Lintzeris, N., Bell, J., Winstock, A., Dietze, P., Mattick, R., Ali, R., Horyniak, D. (2011). Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence, 118(2011), 265-273. [More Information]
  • Douglas, H., Boyle, M., Lintzeris, N. (2011). The health impacts of khat: a qualitative study among Somali-Australians. Medical Journal of Australia, 195(11), 666-669. [More Information]

2010

  • Lintzeris, N., Nielsen, S. (2010). Benzodiazepines, methadone and buprenorphine: interactions and clinical management. American Journal on Addictions, 19(1), 59-72. [More Information]
  • Lintzeris, N. (2010). Commentary on Blanken et al. (2010): long-term heroin-assisted treatment-some more questions and answers. Addiction, 105(2), 309-310. [More Information]
  • Sanson-Fisher, R., Brand, M., Shakeshaft, A., Haber, P., Day, C., Conigrave, K., Mattick, R., Lintzeris, N., Teesson, M. (2010). Forming a national multicentre collaboration to conduct clinical trials: increasing high-quality research in the drug and alcohol field. Drug and Alcohol Review, 29(5), 469-474. [More Information]
  • Forzisi, L., Mitchell, T., Bond, A., Lintzeris, N., Spofforth, N., Strang, J. (2010). Psychological Performance and Sedation Following Injectable Opioid Administration. Heroin Addiction and Related Clinical Problems, 12(3), 5-8.
  • Miller, P., McKenzie, S., Lintzeris, N., Martin, A., Strang, J. (2010). The Community Impact of RIOTT, a Medically Supervised Injectable Maintenance Clinic in South London. Mental Health and Substance Use, 3(3), 248-259. [More Information]
  • Ramasamy, P., Lintzeris, N., Sutton, Y., Taylor, H., Day, C., Haber, P. (2010). The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction, 105(2), 329-334. [More Information]

2009

  • Ridge, G., Gossop, M., Lintzeris, N., Witton, J., Strang, J. (2009). Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Journal of Substance Abuse Treatment, 37(1), 95-100. [More Information]
  • Bammer,, G., Ritter, A., Kutin, J., Lintzeris, N. (2009). Fast-tracking implementation through trial design: the case of buprenorphine treatment in Victoria. Australian and New Zealand Journal of Public Health, 33(1), 34-39. [More Information]
  • Miller, P., Forzisi, L., Zador, D., Lintzeris, N., Metrebian, N., Waal, R., Mayet, S., Strang, J. (2009). Groin injecting in injectable opioid treatment service users in South London. Addiction Research and Theory, 17(4), 381-389. [More Information]
  • Haber, P., Lintzeris, N., Proude, E., Lopatko,, O. (2009). Guidelines for the Treatment of Alcohol Problems, Publications Number: P3 -5625, (pp. vii - 232). Canberra, Australia: Commonwealth Department of Health and Ageing.
  • Degenhardt, L., Larance, B., Bell, J., Winstock, A., Lintzeris, N., Ali, R., Scheuer, N. (2009). Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Medical Journal of Australia, 191(3), 161-165. [More Information]
  • Haber, P., Lintzeris, N., Morley, K. (2009). Pharmacotherapies for alcohol dependence. In Paul Haber, Elizabeth Proude, Nick Lintzeris & Olga Lopatko (Eds.), Guidelines for the Treatment of Alcohol Problems, (pp. 93-106). Australia: Commonwealth of Australia.
  • Lintzeris, N. (2009). Prescription of heroin for the management of heroin dependence: Current status. CNS Drugs, 23(6), 463-476. [More Information]
  • Winstock, A., Lintzeris, N., Lea, T. (2009). Why do patients report transferring between methadone and buprenorphine? Drug and Alcohol Review, 28(6), 686-687. [More Information]

2008

  • Lintzeris, N., Lee, S., Scopelliti, L., Mabbutt, J., Haber, P. (2008). Unplanned admissions to two Sydney public hospitals after naltrexone implants. Medical Journal of Australia, 188(8), 441-444. [More Information]

2005

  • Digiusto, E., Lintzeris, N., Breen, C., Kimber, J., Mattick, R., Bell, J., Ali, R., Saunders, J. (2005). Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addictive Behaviors, 30(3), 443-56. [More Information]

To update your profile click here. For support on your academic profile contact .